tiprankstipranks
Eledon Pharmaceuticals, Inc. (DE:2TK)
NASDAQ:2TK
Germany Market
2TK
Eledon Pharmaceuticals
RESEARCH TOOLSreports

Eledon Pharmaceuticals (2TK) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

2TK Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Eledon
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2TK Stock 12 Month Forecast

Average Price Target

€6.94
▲(106.56% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is €6.94 with a high forecast of €8.68 and a low forecast of €5.21. The average price target represents a 106.56% change from the last price of €3.36.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.6756981,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.94055848,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.20541886,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.18,3.602746007692308,4.025492015384615,4.448238023076923,4.870984030769231,5.293730038461538,5.716476046153846,6.139222053846154,6.561968061538462,6.984714069230769,7.407460076923076,7.830206084615385,8.252952092307693,{"y":8.6756981,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.18,3.4692737292307694,3.7585474584615386,4.047821187692308,4.337094916923077,4.626368646153846,4.915642375384616,5.204916104615385,5.4941898338461534,5.783463563076923,6.072737292307693,6.3620110215384615,6.65128475076923,{"y":6.94055848,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.18,3.335801450769231,3.4916029015384615,3.647404352307692,3.8032058030769234,3.9590072538461536,4.114808704615385,4.270610155384615,4.426411606153846,4.582213056923077,4.7380145076923075,4.893815958461539,5.049617409230769,{"y":5.20541886,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€8.68Average Price Target€6.94Lowest Price Target€5.21
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on DE:2TK
Rami Katkhuda
LifeSci Capital
LifeSci Capital
€5.21
Buy
54.92%
Upside
Reiterated
06/08/26
Analyst Reiterates Buy on Eledon as Tegoprubart Data Impresses; Price Target Maintained at $6
Noble Financial Analyst forecast on DE:2TK
Robert LeBoyer
Noble Financial
Noble Financial
€8.68
Buy
158.21%
Upside
Reiterated
05/22/26
Analysts Offer Insights on Healthcare Companies: Whitehawk Therapeutics (NASDAQ: WHWK) and Eledon Pharmaceuticals (NASDAQ: ELDN)
Guggenheim Analyst forecast on DE:2TK
Vamil Divan
Guggenheim
Guggenheim
€6.94
Buy
106.56%
Upside
Reiterated
03/20/26
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Eledon Pharmaceuticals (ELDN)
Craig-Hallum Analyst forecast on DE:2TK
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
01/23/26
Analysts Conflicted on These Healthcare Names: Ufp Technologies (NASDAQ: UFPT), Eledon Pharmaceuticals (NASDAQ: ELDN) and CareDx (NASDAQ: CDNA)
H.C. Wainwright Analyst forecast on DE:2TK
Yi Chen
H.C. Wainwright
H.C. Wainwright
€7.81
Buy
132.38%
Upside
Reiterated
11/10/25
H.C. Wainwright Remains a Buy on Eledon Pharmaceuticals (ELDN)
Leerink Partners Analyst forecast on DE:2TK
Thomas Smith
Leerink Partners
Leerink Partners
€6.94
Buy
106.56%
Upside
Reiterated
08/15/25
Eledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top Analyst
Cantor Fitzgerald Analyst forecast on DE:2TK
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
07/10/25
Cantor Fitzgerald Keeps Their Buy Rating on Eledon Pharmaceuticals (ELDN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on DE:2TK
Rami Katkhuda
LifeSci Capital
LifeSci Capital
€5.21
Buy
54.92%
Upside
Reiterated
06/08/26
Analyst Reiterates Buy on Eledon as Tegoprubart Data Impresses; Price Target Maintained at $6
Noble Financial Analyst forecast on DE:2TK
Robert LeBoyer
Noble Financial
Noble Financial
€8.68
Buy
158.21%
Upside
Reiterated
05/22/26
Analysts Offer Insights on Healthcare Companies: Whitehawk Therapeutics (NASDAQ: WHWK) and Eledon Pharmaceuticals (NASDAQ: ELDN)
Guggenheim Analyst forecast on DE:2TK
Vamil Divan
Guggenheim
Guggenheim
€6.94
Buy
106.56%
Upside
Reiterated
03/20/26
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Eledon Pharmaceuticals (ELDN)
Craig-Hallum Analyst forecast on DE:2TK
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
01/23/26
Analysts Conflicted on These Healthcare Names: Ufp Technologies (NASDAQ: UFPT), Eledon Pharmaceuticals (NASDAQ: ELDN) and CareDx (NASDAQ: CDNA)
H.C. Wainwright Analyst forecast on DE:2TK
Yi Chen
H.C. Wainwright
H.C. Wainwright
€7.81
Buy
132.38%
Upside
Reiterated
11/10/25
H.C. Wainwright Remains a Buy on Eledon Pharmaceuticals (ELDN)
Leerink Partners Analyst forecast on DE:2TK
Thomas Smith
Leerink Partners
Leerink Partners
€6.94
Buy
106.56%
Upside
Reiterated
08/15/25
Eledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top Analyst
Cantor Fitzgerald Analyst forecast on DE:2TK
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
07/10/25
Cantor Fitzgerald Keeps Their Buy Rating on Eledon Pharmaceuticals (ELDN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eledon Pharmaceuticals

3 Months
Thomas SmithLeerink Partners
Success Rate
8/16 ratings generated profit
50%
Average Return
+5.09%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +5.09% per trade.
1 Year
Robert LeBoyerNoble Financial
Success Rate
12/17 ratings generated profit
71%
Average Return
+35.99%
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +35.99% per trade.
2 Years
Robert LeBoyerNoble Financial
Success Rate
12/17 ratings generated profit
71%
Average Return
+37.16%
Copying Robert LeBoyer's trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +37.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2TK Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
4
3
5
4
Buy
1
3
2
2
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
7
5
7
4
In the current month, 2TK has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2TK average Analyst price target in the past 3 months is 6.94.
Each month's total comprises the sum of three months' worth of ratings.

2TK Financial Forecast

2TK Earnings Forecast

Next quarter’s earnings estimate for 2TK is -€0.14 with a range of -€0.16 to -€0.08. The previous quarter’s EPS was -€0.29. 2TK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2TK has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2TK is -€0.14 with a range of -€0.16 to -€0.08. The previous quarter’s EPS was -€0.29. 2TK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2TK has Performed in-line its overall industry.
No data currently available

2TK Sales Forecast

Next quarter’s sales forecast for 2TK is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 2TK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2TK has Performed in-line its overall industry.
Next quarter’s sales forecast for 2TK is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 2TK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2TK has Performed in-line its overall industry.

2TK Stock Forecast FAQ

What is DE:2TK’s average 12-month price target, according to analysts?
Based on analyst ratings, Eledon Pharmaceuticals, Inc.’s 12-month average price target is 6.94.
    What is DE:2TK’s upside potential, based on the analysts’ average price target?
    Eledon Pharmaceuticals, Inc. has 106.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Eledon Pharmaceuticals, Inc. a Buy, Sell or Hold?
          Eledon Pharmaceuticals, Inc. has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Eledon Pharmaceuticals, Inc.’s share price target?
            The average share price target for Eledon Pharmaceuticals, Inc. is 6.94. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €8.68 ,and the lowest forecast is €5.21. The average share price target represents 106.56% Increase from the current price of €3.36.
              What do analysts say about Eledon Pharmaceuticals, Inc.?
              Eledon Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Eledon Pharmaceuticals, Inc.?
                To buy shares of DE:2TK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.